曲尼司特的药理作用研究进展 - 香港千禾出版集团有限公司

参考文献：

[1]N a k a m u r a , Y u s u k e , K i n o s h i t a , e t al. Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast[J]. Gastric Cancer, 2022(prepublish).

[2]黄明 . 曲尼司特通过 S100A11/TGF-β1/Smad通路抑制血管紧张素Ⅱ诱导的心肌纤维化 [D]. 广州医科大学 , 2022.

[3]历虎 , 张明珠 , 齐长春 . 曲尼司特联合硅酮凝胶超声导入治疗增生性瘢痕疗效探讨 [J]. 中国美容医学 , 2022, 31(10): 35-38.

[4]Raman Swarnalakshmi, Waskitho Arief,Raju Resmi, et al. Analgesic Effect of Tranilast in an Animal Model of Neuropathic Pain and Its Role in the Regulation of Tetrahydrobiopterin Synthesis[J]. International Journal of Molecular Sciences, 2022, 23(11).

[5]Wang Jingjing, Yuan Wenjing, Shen Qingqing, et al. The key role of organic aniontransporter 3 in the drug-drug interaction between tranilast and methotrexate.[J]. Journal of biochemical and molecular toxicology, 2022,36(4).

[6]Zhan Chengchuang, Bai Nan, Zheng Min, et al. Tranilast prevents doxorubicin-induced myocardial hypertrophy and angiotensin II synthesis in rats[J]. Life Sciences, 2021,267(prepublish).

[7]Fahmy Eslam K., El-Sherbiny Mohamed, Said Eman, et al. Tranilast ameliorated subchronic silver nanoparticles-induced cerebral toxicity in rats: Effect on TLR4/NLRP3 and Nrf-2[J]. Neurotoxicology, 2021, 82.

[8]Guo Jie, Cheng Maojun, Liu Peng, et al. A multi-target directed ligands strategy for the treatment of Alzheimer’s disease: Dimethyl fumarate plus Tranilast modified

Dithiocarbate as AChE inhibitor and Nrf2activator[J]. European Journal of MedicinalChemistry, 2022, 242.

[9]T h a p a k P a v a n , B i s h n o i M a h e n d r a ,Sharma Shyam Sunder. Tranilast, a Transient Receptor Potential Vanilloid 2 Channel (TRPV2) Inhibitor Attenuates Amyloid β-Induced Cognitive Impairment: Possible Mechanisms.[J].Neuromolecular medicine, 2021(prepublish).

[10]Matsumura Tsuyoshi, Hashimoto Hiroya, Sekimizu Masahiro, et al. Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label,multicenter study.[J]. Orphanet journal of rare diseases, 2022, 17(1).